Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

4 results about "Placental tissue" patented technology

A method and system for predicting adverse pregnancy outcomes of preeclampsia by fusing placental microenvironment image features and serum biomarkers

The present application relates to the technical field of medical data fusion processing, and discloses a method and system for predicting adverse pregnancy outcomes of preeclampsia by fusing placental microenvironment image features and serum biomarkers, wherein the method comprises: obtaining digital whole field image of placental tissue section and serum biomarker detection data at the same period; constructing a multi-modal sample data set; extracting multi-scale structure features of placental microenvironment; constructing serum biomarker discriminant features; dynamically fusing placental image features and serum marker features; constructing a prediction model for adverse pregnancy outcomes of preeclampsia and outputting a prediction probability. Compared with the prior art which only relies on single image information or single serum biomarker for risk assessment, it is difficult to realize stable prediction of the coordinated changes of placental microenvironment abnormalities and biochemical abnormalities. Due to the multi-scale image structure analysis, the model generalization ability for predicting adverse pregnancy outcomes of preeclampsia is improved.
Owner:THE SEVENTH MEDICAL CENTER OF PLA GENERAL HOSPITAL

Soluble placental ECM

The invention is directed to a composition of soluble placental ECM in storage solution and the methods of manufacture related thereto. The solubilized placental ECM solution is manufactured through a process of partitioning placental ECM from the placental tissue in a high acidic pH environment and performing an ultrafiltration step and diafiltration step through a tangential flow filtration system to increase the pH. The soluble placental ECM retains the native characteristics of placental ECM components and includes collagens (types I, III, V, VI, IX, and X), elastin, laminin, and fibronectin.
Owner:REGENTX PARTNERS LLC

Construction method of mouse placenta-targeted gene interference model and application thereof

PendingCN122250427AOvercome delivery limitationsHigh concentration enrichmentFermentationPlant genotype modificationDiseasePregnancy
The application discloses a kind of construction methods of mouse placenta targeted gene interference model and its application.The method comprises the following steps: first, pregnant mouse is anaesthetized and abdominal operation is carried out, and the uterus containing placenta is exposed;Then, the adeno-associated virus carrying gene interference element is directly injected into target placental tissue;Finally, the wound is sutured to complete model construction.The present application overcomes the problem of low virus delivery efficiency caused by maternal-fetal barrier by intraoperative direct site injection, and realizes the efficient and specific gene interference of placental tissue.The model constructed is targeted and precise, has high interference efficiency and low off-target effect, and provides an effective tool for studying placental gene function and pregnancy-related diseases.
Owner:EIGHTH AFFILIATED HOSPITAL SUN YAT SEN UNIV (SHENZHEN FUTIAN)

Sterile human placental allografts and methods of making thereof

ActiveUS12648969B2Energy modified materialsMammal material medical ingredientsBlood componentCardiac allograft
A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.
Owner:BIOSTEM TECHNOLOGIES INC